This week was supposed to mark the end of compounding pharmacies making copycat versions of Eli Lilly's weight-loss drug Zepbound and its diabete...
Trending
Palo Alto deserves more credit for quarterly results only a year into its new strategy
Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
As GOP weighs Obamacare cuts, the party’s constituents are more likely to use marketplace coverage, poll finds
CrowdStrike drops about 6% on lackluster guidance, ongoing impact from July IT outage
Here are the 3 things we’re watching in the stock market in the week ahead
Salesforce issues weak revenue guidance even as earnings beat estimates
This old-school filmmaking technique is still kicking even as AI takes on a bigger role in movies
The record-breaking run of ‘Ne Zha 2’ may seem like a surprise. It shouldn’t
Oracle soars 30% on cloud growth projections even as earnings miss estimates
Cramer says Broadcom is a buy for new investors, Apple stock’s less ‘treacherous’
